• Earlier this month, American Healthcare REIT, Inc. announced that Chief Executive Officer and President Danny Prosky took a medical leave of absence on February 3, 2026, with Chairman Jeffrey T. Hanson stepping in as Interim CEO and President to work with the senior leadership team on maintaining operations and existing priorities.
• This leadership change comes as the company highlights its diversified healthcare real estate portfolio and sizeable 2025 acquisitions, underscoring an emphasis on continuity while executing its existing growth-focused approach.
• We’ll now examine how Jeffrey Hanson’s appointment as interim CEO and the emphasis on operational continuity may influence American Healthcare REIT’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

American Healthcare REIT Investment Narrative Recap

To own American Healthcare REIT, you need to be comfortable with a thesis built on aging demographics, senior housing exposure and disciplined portfolio management. The interim CEO appointment appears primarily about maintaining continuity, so the immediate impact on the key near term catalyst of portfolio growth and integration, and on the current biggest risk around sustaining high occupancy and rate growth in Trilogy and SHOP, does not look material based on what has been disclosed.

The company’s more than US$950 million of 2025 acquisitions in Integrated Senior Health Campuses and Senior Housing Operating Properties is especially relevant here, since execution on those newer assets is central to both the growth story and the risk around stabilization. With Jeffrey Hanson stepping in as interim CEO, investors may focus on how consistently the existing acquisition and integration playbook is applied across this expanded portfolio.

Yet even with a strong recent share price and growth-focused messaging, investors should be aware that the company’s dependence on high occupancy and robust rate increases in key segments...

American Healthcare REIT's narrative projects $2.7 billion revenue and $203.0 million earnings by 2028.

Uncover how American Healthcare REIT's forecasts yield a $56.08 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for American Healthcare REIT span roughly US$39 to US$92, showing wide dispersion in investor expectations. Against this backdrop, the reliance on continued high occupancy and strong rate growth in Trilogy and SHOP raises important questions about how sensitive future performance could be to even modest shifts in demand or pricing, which readers may want to explore in more detail.

Explore 3 other fair value estimates on American Healthcare REIT - why the stock might be worth 24% less than the current price!

Build Your Own American Healthcare REIT Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your American Healthcare REIT research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free American Healthcare REIT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate American Healthcare REIT's overall financial health at a glance.

No Opportunity In American Healthcare REIT?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• Find 53 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.